| Download | - View full text: Isolation of TGF-β-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing (PDF, 475 KB)
- View supplementary information: Isolation of TGF-β-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing (DOCX, 202 KB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1093/protein/gzw043 |
|---|
| Author | Search for: Henry, Kevin A.1 ; Search for: Hussack, Greg1 ; Search for: Collins, Cathy1 ; Search for: Zwaagstra, John C.1 ; Search for: Tanha, Jamshid1 ; Search for: MacKenzie, C. Roger1 |
|---|
| Name affiliation | - National Research Council Canada. Human Health Therapeutics
|
|---|
| Format | Text |
|---|
| Type | Article |
|---|
| Journal title | Protein Engineering, Design and Selection |
|---|
| ISSN | 1741-0126
1741-0134 |
|---|
| Pages | 1–5 |
|---|
| Subject | antibody; single-domain antibody; VHH; TGF-β; next-generation DNA sequencing; phage display |
|---|
| Abstract | The epitope specificity of therapeutic antibodies is often critical to their efficacy and mode of action. Here, we report the isolation of single-domain antibodies (sdAbs) against a pre-specified epitope of TGF-β3: namely, the site of interaction between the cytokine and its cell-surface type II receptor. By panning a phage-displayed immune llama VhH library against TGF-β3 using competitive elution with soluble dimeric type II receptor ectodomain in tandem with next-generation DNA sequencing, we identified several sdAbs that competed with the receptor for TGF-β3 binding and neutralized TGF-β3 in in vitro cellular assays. In contrast, all other sdAbs identified using conventional panning approaches (i.e., without regard to epitope specificity) did not target the site of receptor:cytokine interaction. We expect this strategy to be generally applicable for identifying epitope-specific sdAbs when binding reagents directed against the epitope of interest are available. The sdAbs identified here are of potential interest as cancer immunotherapeutics. |
|---|
| Publication date | 2016-09-08 |
|---|
| Publisher | Oxford University Press |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 23000759 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction |
|---|
Record identifier | 646f2540-63b6-4b0e-a7ae-731f5c2a6082 | | Record created | 2016-09-14 |
|---|
| Record modified | 2016-09-14 |
|---|
